Since the last issue of the European Pharmaceutical Law Review the vaccination campaigns in the Member States with the four currently authorised COVID-19 vaccines Comirnaty (BioNTech/Pfizer), Vaxzevria (AstraZeneca), as well as the Moderna and the Janssen COVID-19 vaccines, have picked up speed.On 17 May, according to the European Centre for Disease Prevention and Control (ECDC), 36% of the adults in the EU/EEA have received at least 1 vaccination dose and 14,4% are fully vaccinated.While currently four vaccines are under rolling review at the European Medicines Agency (CVnCoV; NVX-CoV2373; Sputnik V (Gam-COVID-Vac); and COVID-19 Vaccine (Vero Cell) Inactivated), the political and regulatory attention is shifting towards preparedness for mutations of the virus and the adaptability of the vaccines for such mutations.

Editorial

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info